A consortium spearheaded by the French private equity firm PAI Partners has reportedly placed an enhanced bid for Sanofi's consumer health division, Opella. PAI is aiming to outdo its American competitor, Clayton Dubilier & Rice (CD&R), to acquire a controlling 50% stake in Opella, renowned for producing Doliprane, one of the most popular painkillers in France.
In this competitive move, PAI has increased its offer for the Opella unit by approximately €200 million, equivalent to $217 million, while promising to maintain the unit’s headquarters and other significant sites within France. Additionally, in their updated proposal, PAI Partners has committed to securing employment by investing at least €60 million over a period of five years.
This revised bid is valid until the end of Sunday night. Meanwhile, the French pharmaceutical conglomerate Sanofi announced last week that it was engaged in negotiations with CD&R regarding the sale of a 50% controlling stake in Opella.
